| Author’s Note: Patient Worthy began following Natera following their presentation at the American College of Medical Genetics conference many years ago.
Natera has been known for its advances in prenatal genetic testing—especially for the technology it developed that allowed a blood sample from the mother to screen for chromosome abnormalities in the fetus such as Down Syndrome, Trisomy 18, Trisomy 13, as well as sex-linked chromosome conditions such as Klinefelter and Turner Syndromes. This non-invasive prenatal testing called NIPT, works because the technique can differentiate the mothers cell DNA from that of the fetus. Prior to the development of NIPT, amniocentesis, which carries considerably more risk, had to be utilized. Natera has been researching how this same technology of DNA identification could be used to help make treatment decisions in cancer. They recently sent out the following press release” We are proud to share the publication of our landmark IMvigor011 phase 3 trial in the New England Journal of Medicine, demonstrating how our Signatera™ test can guide adjuvant treatment decisions, expanding the treatment window and improving survival in muscle-invasive bladder cancer (MIBC).1
|
How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer
